Potential Autoimmunity Resulting from Molecular Mimicry between SARS-CoV-2 Spike and Human Proteins

Viruses. 2022 Jun 28;14(7):1415. doi: 10.3390/v14071415.

Abstract

Molecular mimicry between viral antigens and host proteins can produce cross-reacting antibodies leading to autoimmunity. The coronavirus SARS-CoV-2 causes COVID-19, a disease curiously resulting in varied symptoms and outcomes, ranging from asymptomatic to fatal. Autoimmunity due to cross-reacting antibodies resulting from molecular mimicry between viral antigens and host proteins may provide an explanation. Thus, we computationally investigated molecular mimicry between SARS-CoV-2 Spike and known epitopes. We discovered molecular mimicry hotspots in Spike and highlight two examples with tentative high autoimmune potential and implications for understanding COVID-19 complications. We show that a TQLPP motif in Spike and thrombopoietin shares similar antibody binding properties. Antibodies cross-reacting with thrombopoietin may induce thrombocytopenia, a condition observed in COVID-19 patients. Another motif, ELDKY, is shared in multiple human proteins, such as PRKG1 involved in platelet activation and calcium regulation, and tropomyosin, which is linked to cardiac disease. Antibodies cross-reacting with PRKG1 and tropomyosin may cause known COVID-19 complications such as blood-clotting disorders and cardiac disease, respectively. Our findings illuminate COVID-19 pathogenesis and highlight the importance of considering autoimmune potential when developing therapeutic interventions to reduce adverse reactions.

Keywords: AlphaFold2; COVID-19 complications; coronavirus; machine learning; molecular dynamics; omicron; protein structure comparison; tropomyosin; vaccine design; variant.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antibodies, Viral
  • Antigens, Viral
  • Autoimmunity
  • COVID-19*
  • Heart Diseases*
  • Humans
  • Molecular Mimicry
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / genetics
  • Thrombopoietin
  • Tropomyosin / metabolism

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • Spike Glycoprotein, Coronavirus
  • Tropomyosin
  • spike protein, SARS-CoV-2
  • Thrombopoietin

Grants and funding

This research was funded by the National Science Foundation under Grant No. 2037374 (J.N.-C., P.B., V.S., K.M., G.N., P.C., A.M.M., J.S.-L.).